These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22839416)

  • 41. Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment.
    Pereira D; Daher A; Zanini G; Maia I; Fonseca L; Pitta L; Ruffato R; Marchesini P; Fontes CJ
    Malar J; 2016 Sep; 15():477. PubMed ID: 27639847
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single-Dose Tafenoquine to Prevent Relapse of Plasmodium vivax Malaria.
    Lacerda MVG; Llanos-Cuentas A; Krudsood S; Lon C; Saunders DL; Mohammed R; Yilma D; Batista Pereira D; Espino FEJ; Mia RZ; Chuquiyauri R; Val F; Casapía M; Monteiro WM; Brito MAM; Costa MRF; Buathong N; Noedl H; Diro E; Getie S; Wubie KM; Abdissa A; Zeynudin A; Abebe C; Tada MS; Brand F; Beck HP; Angus B; Duparc S; Kleim JP; Kellam LM; Rousell VM; Jones SW; Hardaker E; Mohamed K; Clover DD; Fletcher K; Breton JJ; Ugwuegbulam CO; Green JA; Koh GCKW
    N Engl J Med; 2019 Jan; 380(3):215-228. PubMed ID: 30650322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border.
    Takeuchi R; Lawpoolsri S; Imwong M; Kobayashi J; Kaewkungwal J; Pukrittayakamee S; Puangsa-art S; Thanyavanich N; Maneeboonyang W; Day NP; Singhasivanon P
    Malar J; 2010 Nov; 9():308. PubMed ID: 21040545
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-dose primaquine regimens against relapse of Plasmodium vivax malaria.
    Krudsood S; Tangpukdee N; Wilairatana P; Phophak N; Baird JK; Brittenham GM; Looareesuwan S
    Am J Trop Med Hyg; 2008 May; 78(5):736-40. PubMed ID: 18458306
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plasmodium vivax infections in U.S. Army troops: failure of primaquine to prevent relapse in studies from Somalia.
    Smoak BL; DeFraites RF; Magill AJ; Kain KC; Wellde BT
    Am J Trop Med Hyg; 1997 Feb; 56(2):231-4. PubMed ID: 9080885
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primaquine treatment and relapse in Plasmodium vivax malaria.
    Rishikesh K; Saravu K
    Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
    Rijal KR; Adhikari B; Ghimire P; Banjara MR; Das Thakur G; Hanboonkunupakarn B; Imwong M; Chotivanich K; Day NPJ; White NJ; Pukrittayakamee S
    J Infect Dis; 2019 Jul; 220(3):448-456. PubMed ID: 30882150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Frequency of malaria relapse due to Plasmodium vivax in a non-endemic region (São Paulo, Brazil)].
    Boulos M; Amato Neto V; Dutra AP; Di Santi SM; Shiroma M
    Rev Inst Med Trop Sao Paulo; 1991; 33(2):143-6. PubMed ID: 1844384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [How much primaquine is needed to eradicate Plasmodium vivax hypnozoites?].
    Muñoz J; Velasco M; Alonso D; Valls ME; Corachán M; Gascón J
    Enferm Infecc Microbiol Clin; 2006 Jan; 24(1):29-30. PubMed ID: 16537060
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand.
    Pukrittayakamee S; Imwong M; Chotivanich K; Singhasivanon P; Day NP; White NJ
    Am J Trop Med Hyg; 2010 Apr; 82(4):542-7. PubMed ID: 20348496
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Association of Impaired Cytochrome P450 2D6 Activity Genotype and Phenotype With Therapeutic Efficacy of Primaquine Treatment for Latent Plasmodium vivax Malaria.
    Baird JK; Louisa M; Noviyanti R; Ekawati L; Elyazar I; Subekti D; Chand K; Gayatri A; Instiaty ; Soebianto S; Crenna-Darusallam C; Djoko D; Hasto BD; Meriyenes D; Wesche D; Nelwan EJ; Sutanto I; Sudoyo H; Setiabudy R
    JAMA Netw Open; 2018 Aug; 1(4):e181449. PubMed ID: 30646129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diagnostic and therapeutic pitfalls associated with primaquine-tolerant Plasmodium vivax.
    Spudick JM; Garcia LS; Graham DM; Haake DA
    J Clin Microbiol; 2005 Feb; 43(2):978-81. PubMed ID: 15695723
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse.
    Walsh DS; Wilairatana P; Tang DB; Heppner DG; Brewer TG; Krudsood S; Silachamroon U; Phumratanaprapin W; Siriyanonda D; Looareesuwan S
    Clin Infect Dis; 2004 Oct; 39(8):1095-103. PubMed ID: 15486831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases.
    de Pina-Costa A; Silvino ACR; Dos Santos EM; Pedro RS; Moreira J; Umana GL; da Silva ADT; da Rosa Santos OHL; de Deus Henriques KM; Daniel-Ribeiro CT; Brasil P; Sousa TN; Siqueira AM
    Malar J; 2021 Aug; 20(1):341. PubMed ID: 34391426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacies of 5- and 14-day primaquine regimens in the prevention of relapses in Plasmodium vivax infections.
    Gogtay NJ; Desai S; Kamtekar KD; Kadam VS; Dalvi SS; Kshirsagar NA
    Ann Trop Med Parasitol; 1999 Dec; 93(8):809-12. PubMed ID: 10715673
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata.
    Kim JR; Nandy A; Maji AK; Addy M; Dondorp AM; Day NP; Pukrittayakamee S; White NJ; Imwong M
    PLoS One; 2012; 7(7):e39645. PubMed ID: 22808048
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India.
    Saravu K; Tellapragada C; Kulavalli S; Xavier W; Umakanth S; Brahmarouphu G; Srinivas NK; Channabasavaiah JP; Bava A; Saadi AV; Guddattu V; Satyamoorthy K; Bhat K
    Malar J; 2018 Sep; 17(1):321. PubMed ID: 30176897
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study.
    Llanos-Cuentas A; Lacerda MV; Rueangweerayut R; Krudsood S; Gupta SK; Kochar SK; Arthur P; Chuenchom N; Möhrle JJ; Duparc S; Ugwuegbulam C; Kleim JP; Carter N; Green JA; Kellam L
    Lancet; 2014 Mar; 383(9922):1049-58. PubMed ID: 24360369
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Repeated Plasmodium vivax malaria relapses in a Peruvian sailor.
    McFarland AP; Sanchez JF; Mercado A; Ventocilla JA; Cavalcanti S; Gonzalez S; Lescano AG
    Malar J; 2015 Dec; 14():478. PubMed ID: 26620122
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of artemether-lumefantrine for the treatment of uncomplicated Plasmodium vivax malaria.
    Bassat Q
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1325. PubMed ID: 22216359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.